Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NRXGQ: BK PLAN effective. All shares cancelled:
http://otce.finra.org/DLDeletions
I honestly can't say this surprises me. I'll post some more on it later...but peeps can see what I see and draw their own conclusions from there. Hint: look at stuff from the past month.
Also, their August 2016 MOR was 'interesting'...so never took my eyes off of it.
A lot of accumulation has been taking place here last week and this...interesting timing. Waiting to see. Mentioned before, company could have just done. Chapter 7, but didn't.
from 0,08 to 0,20 is nice
Holy mother of Jesus. You ain't kidding!!
Here we go!!!!!!
Nice!! There was a time everyone wrote off KBIO after their bk announcement. All it takes is for someone of 'similar thinking' to come across this one. As I mentioned in a prior post, there's a phase III asset 'on the table' and a very tiny float here. Company already spent hundreds of millions, that another company now doesn't have to spend, developing that asset. Their debt is about 8 mil with a few mil of cash in hand.
Markets can decide if this is worth a ticket to ride! Can be a 'game-changer' if it does 'catch that wind in it's sails'.
Bid 0,13 ask 0,132 volume 255.627
Today + 46,67%
IMO, buyout coming. This bad boy has such a small float too. Watching her very closely these days.
wonder if NRXCQ .075 gets gap fill to high .30s when bios heat up
NRX changed to NRXGQ, bankruptcy. Delisted from the Nasdaq to the OTC:
http://otce.finra.org/DLAdditions
I see you out here, all by yourself, behaving 'strangely'!! Are we there yet?
$NRX
Can anyone tell me the difference between a Chapter 11 and a Chapter 7? Anyone? Anyone?
Gonna go some 'volume watching' today. Fridays can be full of excitement. This one offers so many 'opportunities' to a range of market-place players...least of which is the Phase III asset. Let's see.
This is like someone putting their sweat and toil into a home in an up-and-coming neighborhood, then walking away saying 'I can't afford it any more'.
Someone will eventually see the value and scoop it up. Yes, 'the neighborhood' might change and generate little interest, but 'phase III' suggests it actually got ambit better. We'll see. Volume starting to expand here too. Like my odds at current pps.
Guess you haven't been watching the accumulation here over the past couple days. Also, just and FYI...that was also the plan for KBIO at one point...bk took it to pennies. see where it's trading while in BK?
No recovery! The company says to liquidate all its assets and shut down. Commons will get Nothing and will be Cancelled and Wiped out as the company will be closed.
A plan of liquidation will likely result in holders of the Company's capital stock receiving no distribution on account of their interests and cancellation of their existing stock.
Shame no one recognized the value here after the bk news took pps to new lows. This one's a no-brainier. A PHASE III asset in the fast-track. Debt is negligible.
Oh well...can lead a horse to water. GL to you and me both!!
NNRX, the insiders and funds are holding 80% of the O/S, or 10.4 million shares, out of 13 m O/S, They didn't sell, so
They won't let their Huge money gone like this. They'll push it to go higher.
10.4 million x $12 (IPO pps) = $124.8 Million, while their shares are now only $1.56 m.
Huge bouncing soon!
Sometimes the markets can be a bit 'short sighted'. So here we have a company, unable to pay it's 8mil debt and continue with operations. Wonder what that 'fast track phase III asset' they already spent millions developing might be worth'?
Just sayin'
The company is trying hard to get rid of itself as soon as possible, as they did by firing CEO and CSO in Apr. I'm afraid they will close the company shortly after this BK.
Sorry...that got away from me. Was asking doesn't this meet the profile of the kind of company / play that that fella, Martin Shkreli, radars? He also still might be in the market for a shell to fit his Turning Pharma Co?
Doesn't this one meet the exact profile o
Oopus! NRX filed Bankruptcy today. Didn't expect it did it so soon!
Look like there is not going to be any regular bouncing for this little low float stock. they filled a bk. We all know how the turnout is on one of those. Major losses and a few up click bounces.
Good luck to all investors and shareholders.
accumulations looks like finish. intraday bounce today. NRX NASDAQ low floater for next week on watch.
Yep, it's just trading at 50% of cash and insiders/funds holding 80% of the O/S, will skyrocket to dollars, once the merger deal is done. Just a bit patient.
NRX is searching to complete a reverse merger, currently.
On Feb. 10, 2014, it completed an initial public offering, selling shares for $12 and raising $33 million. By the fourth quarter that year, shares traded as high as $17.98. Using Dec. 31, 2014, as a date of demarcation, NephroGenex was the best-performing IPO of the five Triangle companies to go public that year, a group that included high fliers like INC Research and PRA Health Sciences.
The company reported $11.5 million in cash, cash equivalents and short-term investments on hand. At a share price of 40 cents, where the stock closed Thursday, the company has a market value of only about $5 million, meaning it was trading at a value less than half of the available cash and short-term assets.
The insiders/funds holding 10.4 million shares out of 13 m O/S.
Once the merger deal is settled, it'll skyrocket, as the insiders and funds will try hard to get their huge money back. Not expecting it'll bounce back to $12, but $4-$5 is very possible.
We'll see.
NRX, the insiders and funds are holding 80% of the O/S, or 10 million shares, out of 13 m O/S, Huge!
WTF are you talking about? Dis you drink a Crystal meth milk shake or something?
NRX just halted its trial and fired CEO and CSO in Apr. and stopped all operations with Big problems.
Right now, the company is just a shell without nothing. Next, may File Bankruptcy or be shut down.
It's just pump in order to Dump!!! before BK or shut-down.
* * $NRX Video Chart 04-26-16 * *
Link to Video - click here to watch the technical chart video
This play couldn't find the steam to break and hold .71 so the trend has been broken.
GLTA
TrendTrade2016
NRX looking good. nice found.
This ticker setting up for a short term trend. Watch for a break of .71 to define this move.
GLTA
TrendTrade2016
NRX, $0.54, moving, O/S: 13 m. IPO at $12 and went high to $18.
It completed an initial public offering, selling shares for $12 and raising $33 million. By the fourth quarter that year, shares traded as high as $17.98. Using Dec. 31, 2014, as a date of demarcation, NephroGenex was the best-performing IPO of the five Triangle companies to go public that year, a group that included high fliers like INC Research and PRA Health Sciences.
Huge bouncing back to dollars!!!
$0.81, worst trap I ever experienced on GOOD news (bought on the spike on Friday) SUCH A TURD!!!!!!!!!!!!!!!!!!!!!!!!!!
So, why it is now down to a LOWEST LOW of $0.85?
Is the company DILUTING???
This trading makes NO SENSE, down to 52 weeks low and by far ($0.86) on GOOD news.
Untold DILUTION here?
SM that really bothered you..,. as in , you could not live knowing that sh&^%t usually is ON a stick and not IN a stick.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
165
|
Created
|
12/31/14
|
Type
|
Free
|
Moderators |
RALEIGH, N.C.--(BUSINESS WIRE)--
NephroGenex, Inc. (NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin. This study assesses a drug’s risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities.
Pyridorin showed no effect on the QT/QTc interval at the expected therapeutic dose of 300 mg and at a higher dose of 1200 mg. In previous Phase 1 and Phase 2 studies, Pyridorin has shown no effect on the QT/QTc interval in patients with diabetic nephropathy.
“These are important study results that support the use of Pyridorin in patients with diabetic nephropathy, many of whom suffer from cardiovascular disease. They are also important given the concerns over cardiac safety seen with other therapies in development for this disease,” said Chief Executive Officer Pierre Legault. “The overall excellent safety profile we are continuing to see, along with the promising efficacy shown in our Phase 2 trials, continues to suggest that Pyridorin has the potential to broadly address the unmet therapeutic needs of the more than 6 million diabetic patients with kidney disease.”
About Diabetic Nephropathy
Diabetic nephropathy is a chronic, degenerative disease of the kidney caused by diabetes. There are approximately 6 million patients with diabetic nephropathy in the United States (approximately 33% of diagnosed diabetics) and this population is expected to grow. Patients suffering from diabetic nephropathy progress to End Stage Renal Failure (and require dialysis) or death. There are currently no adequate treatments for this disease.
About Pyridorin®
Pyridorin inhibits pathogenic oxidative chemistries, which are collectively elevated in diabetic patients and induce pathological changes implicated in the development of diabetic nephropathy. Pyridorin inhibits a broad range of these chemistries which we believe accounts for its effectiveness in slowing the progression of nephropathy in diabetic patients as shown in our Phase 2 studies. Our lead drug candidate was also found to be safe and well tolerated in these same studies.
About NephroGenex, Inc.
NephroGenex (NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates. Our clinical program has been done in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of Pyridorin, which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.
Cautionary Note on Forward-Looking Statements
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |